Literature DB >> 1313860

Efficacy of '8-drugs-in-one-day' combination in treatment of recurrent GBM patients.

A Boiardi1, A Silvani, I Milanesi, G Broggi, L Fariselli.   

Abstract

Thirty-five adult recurrent GBM patients, divided randomly in two groups of 19 and 16 cases, had been treated with two regimens of chemotherapy: a) 'eight-drugs-in-one-day'; b) procarbazine + CCNU + vincristine (PCV) respectively. Chemotherapy was planned at the tumour relapse and delivered as long as tolerated without irreversible sequelae or until the CT scan showed tumor progression. Multiple agents are used simultaneously in the therapeutic approach using 'eight-in-one' to kill as many heterogeneous cells of malignant glial tumor as possible and minimize the emergence of cellular resistance to chemotherapy. Rate response to chemotherapy and the median adjunctive survival time (6.5 and 6 months, respectively) are not significantly different in the two arms of this study. Our experience with such an aggressive multi-drugs combination 'eight-in-one-day' was disappointing if compared with less toxic, better tolerated and easy delivered (PCV) regimen.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1313860     DOI: 10.1007/bf00172666

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  13 in total

1.  An experimental biological basis for increasing the therapeutic index of clinical cancer therapy.

Authors:  B T Hill; L A Price
Journal:  Ann N Y Acad Sci       Date:  1982-12-10       Impact factor: 5.691

2.  Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy.

Authors:  T W Pendergrass; J M Milstein; J R Geyer; A F Mulne; E J Kosnik; J D Morris; R L Heideman; F B Ruymann; J T Stuntz; W A Bleyer
Journal:  J Clin Oncol       Date:  1987-08       Impact factor: 44.544

3.  Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors.

Authors:  P H Gutin; C B Wilson; A R Kumar; E B Boldrey; V Levin; M Powell; K J Enot
Journal:  Cancer       Date:  1975-05       Impact factor: 6.860

4.  Multidisciplinary treatment for central nervous system tumours with nitrosourea compounds.

Authors:  P Paoletti; G Robustelli della Cuna; R Knerich; M R Strada
Journal:  Acta Neurochir (Wien)       Date:  1978       Impact factor: 2.216

5.  Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors.

Authors:  V A Levin; M S Edwards; D C Wright; M L Seager; T P Schimberg; J J Townsend; C B Wilson
Journal:  Cancer Treat Rep       Date:  1980 Feb-Mar

6.  Application of theoretical models to chemotherapy protocol design.

Authors:  J H Goldie; A J Coldman
Journal:  Cancer Treat Rep       Date:  1986-01

Review 7.  Chemotherapy for malignant gliomas.

Authors:  P L Kornblith; M Walker
Journal:  J Neurosurg       Date:  1988-01       Impact factor: 5.115

8.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

Authors:  J H Goldie; A J Coldman
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

9.  Increased activation of 1-beta-D-arabinofuranosylcytosine by hydroxyurea in L1210 cells.

Authors:  C T Walsh; R W Craig; R P Agarwal
Journal:  Cancer Res       Date:  1980-09       Impact factor: 12.701

10.  New thoughts on resistance to chemotherapy.

Authors:  J H Goldie
Journal:  Hosp Pract (Off Ed)       Date:  1983-05
View more
  5 in total

1.  Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data.

Authors:  A Boiardi; A Salmaggi; A Pozzi; G Broggi; A Silvani
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

Review 2.  Procarbazine, lomustine and vincristine for recurrent high-grade glioma.

Authors:  Saurabh Parasramka; Goutham Talari; Myrna Rosenfeld; Jing Guo; John L Villano
Journal:  Cochrane Database Syst Rev       Date:  2017-07-26

3.  Evaluation of response to postradiation eight in one chemotherapy in childhood brain tumors.

Authors:  I Ayan; E Darendeliler; R Kebudi; O Barlas; N Ayan; C Bayindir; S Bahar; N Bilge
Journal:  J Neurooncol       Date:  1995-10       Impact factor: 4.130

4.  Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.

Authors:  Antonio Silvani; Marica Eoli; Andrea Salmaggi; Elena Lamperti; Elio Maccagnano; Giovanni Broggi; Amerigo Boiardi
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

Review 5.  The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

Authors:  Jeffrey J Olson; Lakshmi Nayak; D Ryan Ormond; Patrick Y Wen; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2014-04-17       Impact factor: 4.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.